Crassula Pharmaceuticals Launches Estarol, Atorvastatin 20mg and 40mg Coated Tablets, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a leader in pharmaceutical manufacturing, announces the launch of Estarol, atorvastatin in 20mg and 40mg coated tablets, reinforcing its commitment to advancing cardiovascular health in Honduras. Estarol is formulated to lower high cholesterol and reduce the risk of heart disease, showcasing Crassula Honduras’s dedication to offering comprehensive healthcare solutions.

Atorvastatin, the active ingredient in Estarol, is a statin medication that works by reducing the levels of bad cholesterol (LDL) and triglycerides in the blood while increasing good cholesterol (HDL). The availability of Estarol in both 20mg and 40mg dosages allows healthcare providers to tailor treatment to individual patient needs, enhancing the effectiveness of cholesterol management strategies.

“Estarol is a testament to Crassula Honduras’s ongoing commitment to provide innovative, accessible healthcare solutions,” said Ricardo Fiallos, Sales Director at Crassula Honduras. “With the launch of Estarol, we aim to address the growing need for effective cholesterol management options, contributing to the prevention of cardiovascular diseases and improving patient outcomes in Honduras.”

Estarol’s coated tablet formulation ensures ease of administration and patient compliance, with dosing flexibility to meet the therapeutic needs of a wide patient population.

For more information about Estarol and other Crassula Honduras products, please visit visit www.crassulapharma.com or contact sales@crassulapharma.com 

About Crassula Honduras

Crassula Honduras is committed to delivering high-quality healthcare products, emphasizing innovation, quality, and patient safety to enhance the health and well-being of individuals in Honduras and beyond. Our broad product portfolio addresses various therapeutic needs, fulfilling the healthcare requirements of our community.